Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
ABSTRACT Aim We investigated the impact of proteinuria on the therapeutic effect before lenvatinib administration as second‐line treatment after atezolizumab‐bevacizumab. Methods We examined 64 patients who were administered lenvatinib as second‐line treatment after discontinuation of atezolizumab a...
Saved in:
Main Authors: | Hironori Ochi, Masayuki Kurosaki, Takaaki Tanaka, Nobuharu Tamaki, Kaoru Tsuchiya, Yutaka Yasui, Hiroyuki Marusawa, Toshifumi Tada, Shinichiro Nakamura, Takehiro Akahane, Eisuke Okamoto, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Namiki Izumi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | JGH Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/jgh3.70098 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
by: Hideko Ohama, et al.
Published: (2025-01-01) -
Approach to investigation and management of proteinuria in pregnancy
by: Isabela Bertoni, et al.
Published: (2025-01-01) -
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)